1-Chlorocyclohexa-1,3-diene | 89309-36-4

• 分子结构分类: 有机化合物 - 有机卤素化合物 - 乙烯基卤化物
• 英文名称: 1-Chlorocyclohexa-1,3-diene
• CAS: 89309-36-4
• 化学式: C₆H₇Cl
• 分子量: 114.57
• InChiKey: GGYAEMVRZZZXGB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  7
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  0
• 氢给体数：
  0
• 氢受体数：
  0

文献信息

• NOVEL PYRIMIDINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION INCLUDING SAME AS AN ACTIVE INGREDIENT
  申请人：Hanmi Pharmaceutical Co., Ltd.

  公开号：EP2738174A2

  公开（公告）日：2014-06-04

  The present invention relates to a compound represented by formula (I) for inhibiting the activity of diacylglycerol O-acyltransferase type 1 (DGAT1), and pharmaceutically acceptable salts thereof, and a pharmaceutical composition comprising same as an active ingredient. The compound of the present invention may be used effectively in the treatment or prevention of a disease or condition mediated by the activity of DGAT1 such as obesity, type II diabetes, dyslipidemia, metabolic syndrome, and the like, without any adverse effects: wherein A, B, X, and R5 to R7 are the same as defined in the specification.

  本发明涉及一种化合物，其由式(I)表示，用于抑制二酰基甘油酰基转移酶1型（DGAT1）的活性，以及其药学上可接受的盐，以及包含其作为活性成分的药物组合物。本发明的化合物可以有效用于治疗或预防由DGAT1活性介导的疾病或病况，如肥胖、2型糖尿病、血脂异常、代谢综合征等，而不产生任何不良影响： 其中A、B、X和R5到R7与规范中定义的相同。
• [EN] UREA DERIVATIVE OR PHARMACOLOGICALLY ACCEPTABLE SALT THEREOF<br/>[FR] DÉRIVÉ D'URÉE OU SEL PHARMACOLOGIQUEMENT ACCEPTABLE DE CE DERNIER
  申请人：KYORIN SEIYAKU KK

  公开号：WO2016189877A1

  公开（公告）日：2016-12-01

  The present invention provides a urea compound or a pharmacologically acceptable salt thereof that has a formyl peptide receptor like 1 (hereinafter may be abbreviated as FPRL1) agonist effect, a pharmaceutical composition containing the urea compound or the pharmacologically acceptable salt thereof, and a pharmaceutical use thereof. It has been found that a urea derivative represented by the general formula (I) below or a pharmacologically acceptable salt thereof has a superior FPRL1 agonist effect. Compound (I) or a pharmacologically acceptable salt thereof is highly useful for treatment, prevention, or suppression of inflammatory diseases, chronic airway diseases, cancers, septicemia, allergic symptoms, HIV retrovirus infection, circulatory disorders, neuroinflammation, nervous disorders, pains, prion diseases, amyloidosis, immune disorders and the like.

  本发明提供了一种尿素化合物或其药理学上可接受的盐，具有类似甲酰肽受体1（以下简称为FPRL1）的激动剂作用，含有该尿素化合物或其药理学上可接受的盐的药物组合物，以及其药用。已发现下述一般式（I）所代表的尿素衍生物或其药理学上可接受的盐具有优越的FPRL1激动剂作用。化合物（I）或其药理学上可接受的盐对于治疗、预防或抑制炎症性疾病、慢性气道疾病、癌症、败血症、过敏症状、HIV逆转录病毒感染、循环障碍、神经炎症、神经障碍、疼痛、朊病、淀粉样变性、免疫障碍等方面非常有用。
• [EN] SHP2 PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF<br/>[FR] INHIBITEURS DE LA PROTÉINE SHP2 PHOSPHATASE ET LEURS PROCÉDÉS D'UTILISATION
  申请人：RELAY THERAPEUTICS INC

  公开号：WO2019165073A1

  公开（公告）日：2019-08-29

  The present disclosure relates to novel compounds and pharmaceutical compositions thereof, and methods for inhibiting the activity of SHP2 phosphatase with the compounds and compositions of the disclosure. The present disclosure further relates to, but is not limited to, methods for treating disorders associated with SHP2 deregulation with the compounds and compositions of the disclosure.

  本公开涉及新颖化合物及其药物组合物，以及利用本公开的化合物和组合物抑制SHP2磷酸酶活性的方法。本公开还涉及但不限于利用本公开的化合物和组合物治疗与SHP2失调相关的疾病的方法。
• [EN] FLUOROMETHYL-SUBSTITUTED PYRROLE CARBOXAMIDES III<br/>[FR] PYRROLE CARBOXAMIDES III SUBSTITUÉS PAR DU FLUOROMÉTHYLE
  申请人：GRUENENTHAL GMBH

  公开号：WO2015090603A1

  公开（公告）日：2015-06-25

  The invention relates to pyrrole carboxamides bearing a fluoromethyl- moiety as voltage gated calcium channel blockers, to pharmaceutical compositions containing these compounds and also to these compounds for use in the treatment and/or prophylaxis of pain and further diseases and/or disorders.

  该发明涉及带有氟甲基基团的吡咯羧酰胺作为电压门控钙通道阻滞剂，以及含有这些化合物的药物组合物，还涉及这些化合物用于治疗和/或预防疼痛以及其他疾病和/或紊乱。
• METHOD FOR IMPROVING THE PRODUCTION OF A CHLORINATED ALKANE BY CHLORINATION OF A CHLOROALKENE USING A DILUENT
  申请人：BLUE CUBE IP LLC

  公开号：US20190300459A1

  公开（公告）日：2019-10-03

  The present invention provides improved processes for the production of a chlorinated alkane by chlorination of a chloroalkene in the presence of a diluent.

  本发明提供了一种在稀释剂存在下通过氯化氯烯烃的氯化反应来生产氯化烷的改进工艺。